Q4 2023 13F Holders as of 12/31/2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
157M
-
Number of holders
-
1
-
Total 13F shares, excl. options
-
55K
-
Shares change
-
-647K
-
Total reported value, excl. options
-
$939K
-
Value change
-
-$6.92M
-
Number of sells
-
-2
-
Price
-
$17.08
Significant Holders of TG THERAPEUTICS, INC. - Common Stock (TGTX) as of Q4 2023
2 filings reported holding TGTX - TG THERAPEUTICS, INC. - Common Stock as of Q4 2023.
TG THERAPEUTICS, INC. - Common Stock (TGTX) has 1 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 55K shares
of 157M outstanding shares and own 0.03% of the company stock.
Largest 10 shareholders include VANGUARD GROUP INC (13.7M shares), BlackRock Inc. (10.8M shares), STATE STREET CORP (8.25M shares), Darwin Global Management, Ltd. (4.05M shares), Pictet Asset Management Holding SA (3.39M shares), WELLINGTON MANAGEMENT GROUP LLP (3.14M shares), GEODE CAPITAL MANAGEMENT, LLC (3.1M shares), MILLENNIUM MANAGEMENT LLC (2.93M shares), Opaleye Management Inc. (2.22M shares), and Paradigm Biocapital Advisors LP (2.17M shares).
This table shows the top 1 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.